IGF-1 LR3

IGF-1 LR3

IGF1-LR3 acts as a potent agonist of the IGF-1 receptor due to its structural similarity to endogenous IGF-1. The critical modifications a 13-amino acid N-terminal extension and Arg substitution at the third residue drastically lower its binding affinity for circulating IGFBPs, thereby increasing the proportion of free, receptor-accessible peptide. Upon binding to the IGF-1 receptor, IGF1-LR3 activates downstream PI3K/Akt and MAPK pathways, promoting protein synthesis, cell survival, proliferation, and differentiation. These effects underlie the compound’s pronounced anabolic and anti-catabolic properties seen in a range of experimental models, especially where IGF-1’s activity is otherwise neutralized by IGFBPs.

Biological Activity:

            IGF1-LR3 has robust in vivo and in vitro anabolic effects, including the reversal of dexamethasone-induced catabolic states, increased nitrogen retention, attenuation of muscle protein breakdown, and stimulation of cell survival and extracellular matrix production in vascular smooth muscle and other tissues. Its resistance to IGFBPs leads to 2-3 fold greater potency than native IGF-1 in stimulating weight gain, protein accrual, and tissue regeneration in experimental models. IGF1-LR3 also exhibits protective, anti-apoptotic, and matrix-stabilizing effects in models of vascular disease and tissue repair.

Storage: Store at -20°C or lower; protect from repeated freeze-thaw cycles.

Drug Categories: Experimental growth factor analog; IGF-1R agonist

Additional Notes:

• Not approved for clinical use in humans; for research purposes only.
• Designed for maximized selectivity to white adipose vasculature.

Summary Table:

Disclaimer: 

For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.